5/6/2013

A study in the journal Supportive Care in Cancer found that initial therapy with Revlimid may not hamper the ability of patients with myeloma to produce enough stem cells to allow transplants. Only 2% of 319 patients were not able to produce adequate stem cells for a transplant. The researchers are urging a reassessment of guidelines from the International Myeloma Working Group that recommend that stem cell collection occur within four cycles of Revlimid treatment.

Full Story:
MyelomaBeacon.com

Related Summaries